Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(R)-alpha-methylhistamine is a synthetic, chiral, small molecule that acts as a potent and selective agonist for the **histamine H3 receptor**. Its (R)-enantiomer shows much higher activity than the (S)-enantiomer. The compound is mainly utilized as a pharmacological tool in research to study histamine H3 receptor pathways, including neuronal histamine release, gastric acid secretion modulation, and gastroprotective processes. It demonstrates high affinity with a \( K_i \) in the nanomolar range and exhibits over 200-fold selectivity for H3 over other histamine receptors[11][7][20][1][18][19]. Research applications have included investigations into gastrointestinal physiology, CNS function, and immunological responses. The molecule is for research use only and not approved for therapeutic use. Developers and manufacturers supply this compound as dihydrochloride and dihydrobromide salts for laboratory and pharmacological studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on r(-)-alpha-methyl-histamine.